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Abstract: Afibrinogenemia is a rare bleeding disorder with an estimated prevalence of 
1:1,000,000. It is an autosomal recessive disease resulting from mutations in any of the 
3 genes that encode the 3 polypeptide chains of fibrinogen and are located on the long 
arm of chromosome 4. Spontaneous bleeding, bleeding after minor trauma and excessive 
bleeding during interventional procedures are the principal manifestations. We review 
the management of afibrinogenemia. Replacement therapy is the mainstay of treatment of 
bleeding episodes in these patients and plasma-derived fibrinogen concentrate is the agent 
of choice. Cryoprecipitate and fresh frozen plasma are alternative treatments that should be 
used only when fibrinogen concentrate is not available. Secondary prophylactic treatment may 
be considered after life-threatening bleeding whereas primary prophylactic treatment is not 
currently recommended. We also discuss alternative treatment options and the management 
of surgery, pregnancy and thrombosis in these patients. The development of new tests to 
identify higher risk patients and of safer replacement therapy will improve the management 
of afibrinogenemia in the future.
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Introduction
Afibrinogenemia is a rare bleeding disorder with an estimated prevalence 
of 1:1,000,000.1,2 It is an autosomal recessive disease and most patients are 
commonly descendent of consanguineous marriages.1–3 Afibrinogenemia results 
from mutations in any of the 3 genes (FGA, FGB and FGG) that encode the 
3 polypeptide chains of fibrinogen (Aα, Bβ and γ) and are located in a 50 kb 
region on 4q31.3.4 These mutations affect the synthesis, assembly, intracellular 
processing, stability or secretion of fibrinogen.4 Fibrinogen plays an important role 
in clot formation through its conversion to fibrin by the action of thrombin.5,6 It is 
also important in primary hemostasis since it contributes to platelet aggregation 
by binding to glycoprotein IIb/IIIa on the activated platelet surface.5,6 The 
diagnosis of afibrinogenemia is based on the presence of prolonged prothrombin, 
thrombin, reptilase and activated partial thromboplastin time, undetectable 
functional fibrinogen and absence or trace amounts of immunoreactive fibrinogen.5 
Platelet adhesion and ADP-induced platelet aggregation are also impaired in 
these patients whereas thrombin- and collagen-stimulated platelet aggregation 
is normal.7–10Vascular Health and Risk Management 2009:5 844
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We review the principal clinical manifestations and the 
management of patients with afibrinogenemia. We also discuss 
the case for prophylactic treatment and the management of 
pregnancy in these patients.
Clinical manifestations
The commonest manifestations of afibrinogenemia are 
umbilical stump bleeding (which can be life threatening) 
and bleeding from mucosal surfaces, particularly menor-
rhagia, epistaxis and bleeding in the oral cavity.3 Muscu-
loskeletal bleeding (including hemarthroses) is observed 
in around half of the patients3,11 and in some series it was 
more frequent than mucosal bleeding.12 These discrepant 
results on the relative frequency of bleeding complications 
are partly due to the small number of patients included in 
the reported series.3,12 Bleeding from the gastrointestinal and 
urinary tract is less frequent3 whereas intracranial bleeding 
is rare.3,12–15 However, recurrent episodes of intracranial 
hemorrhage have been reported.12,14–16 Hemoperitoneum 
and hemorrhagic corpus luteum following the rupture of a 
follicle during ovulation are other rare manifestations.13,17–20 
The bleeding tendency is highly variable in afibrinogenemia 
(ranging between very few up to several episodes/year) even 
among patients with the same mutation.5,12,21 The presence 
of modifier genes (yet unidentified) or the coexistence of 
thrombophilic disorders has been implicated as an expla-
nation for this variability.21 Besides spontaneous bleeding, 
bleeding after minor trauma and excessive bleeding during 
interventional procedures are other principal manifestations 
of afibrinogenemia.2,3,11
Paradoxically, spontaneous thrombotic complications 
have also been reported in patients with afibrinogenemia, 
including thrombosis in peripheral arteries and in cerebral and 
hepatic veins.3,22,23 Fibrin down-regulates thrombin generation 
by reducing prothrombin activation and also binds and seques-
ters thrombin.24,25 This antithrombin activity of fibrin (anti-
thrombin I) is absent in patients with afibrinogenemia, who 
exhibit increased prothrombin activation and thrombin gen-
eration.7,24,25 In addition, free thrombin may stimulate platelets 
to release several growth factors that induce vascular smooth 
muscle cell proliferation and intimal hyperplasia.26 All these 
abnormalities may contribute to the development of throm-
botic complications.7,24–26 Ex vivo studies also suggested that 
larger and loosely packed platelet thrombi are formed in the 
absence of fibrinogen.27 In some patients, the coexistence of 
thrombophilic disorders (eg, protein C deficiency, hepatitis C 
infection with mixed cryoglobulinemia and anticardiolipin 
antibodies) might also contribute to thrombosis.28,29
Fibrinogen also plays a role in wound healing, with reports 
of impaired wound healing following surgery and slow-healing 
leg ulcers in patients with afibrinogenemia.3,30,31 Spontaneous 
splenic rupture is another rare manifestation.13,32–34
Treatment
Replacement therapy
Replacement therapy is the mainstay of treatment of bleeding 
episodes in patients with afibrinogenemia and includes 
plasma-derived fibrinogen concentrate, cryoprecipitate and 
fresh frozen plasma (FFP).5,35,36 The quantity of fibrinogen 
required can be calculated as follows: 
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Treatment should be administered daily or every other 
day based on the indication, response, potential fibrinogen 
consumption and monitoring of fibrinogen activity.5,36 Since 
the half-life of fibrinogen is approximately 4 days, alternate 
day administration should be sufficient in the absence of 
consumption.36 For spontaneous bleeding, recommended 
target fibrinogen levels are 1 g/L until hemostasis is 
achieved and 0.5 g/L until the bleeding surface is completely 
healed.5,36 However, many physicians appear to aim at 
higher fibrinogen levels possibly because of concerns about 
achieving hemostasis at lower levels; however, this strategy 
might increase the risk of thrombosis (see below).12
Fibrinogen concentrate is the replacement therapy 
of choice in patients with afibrinogenemia.35,36 Its main 
advantage over other replacement therapies is that it is virally 
inactivated; other advantages are a smaller infusion volume 
and a lower risk of allergic reactions.2 Viral inactivation of 
existing fibrinogen concentrates is performed either with 
solvent detergent exposure (alone or in combination with 
dry heating and/or nanofiltration) or with pasteurization.21 
However, non–lipid-enveloped viruses such as parvovirus 
B19 and hepatitis A virus may survive in currently used 
inactivation processes.35,37,38 Moreover, since all fibrino-
gen concentrates are plasma-derived, there is a theoretical 
potential for transmission of new non-viral pathogens 
(eg, prions).21,35 There are 5 fibrinogen concentrates currently 
available, Haemocomplettan® P (CSL Behring, Marburg, 
Germany), Clottagen® and FIBRINOGENE T1® (LFB, Les 
Ullis, France), Fibrinogen HT® (Benesis, Osaka, Japan) and 
FibroRAAS® (Shangai RAAS, Shangai, China).21,39 These 
products are not available or licensed in all countries and 
there are no studies directly comparing their efficacy. In an Vascular Health and Risk Management 2009:5 845
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open uncontrolled study, the half-life of Haemocomplettan 
P was between 2.5 and 5.2 days, ie, similar to the half-life 
of fibrinogen in normal individuals.40 A dose of 1 mg/kg 
Haemocomplettan P increased fibrinogen concentration 
by 0.015 g/L and normalized coagulation parameters 
during the day of infusion.40 In another open, uncontrolled, 
retrospective study, Haemocomplettan P was effective in 
both the treatment of spontaneous bleeding episodes and 
as prophylaxis before surgical procedures or against spon-
taneous bleeding.41 The median post-infusion fibrinogen 
levels were 1.45 g/L and a reduction in both thrombin and 
activated partial thromboplastin time was observed after 
infusion.41 The median single and total doses per episode 
were 2.0 and 4.0 g per patient, respectively, and the median 
duration of treatment was 1 day.41 One patient given 
prophylactic infusions developed an anaphylactic reaction 
and another patient undergoing osteosynthesis developed 
deep vein thrombosis and pulmonary embolism despite 
postoperative prophylaxis with heparin.41 No other side 
effects were reported.41 In a more recent open, uncontrolled, 
prospective study, target fibrinogen levels were achieved 
within 1 hour after the infusion of FIBRINOGENE T1 and 
the between-patient variability in pharmacokinetics was 
very small.39 The mean half-life of fibrinogen was 3.4 days 
and coagulation parameters were normalized for 6 to 
10 days after the infusion.39 Administration of fibrinogen 
concentrate was also shown to correct platelet adhesion and 
ADP-induced platelet aggregation even at fibrinogen levels 
as low as 10% of normal.8
Cryoprecipitate and FFP represent alternative replacement 
therapies and should be given only in emergencies when 
fibrinogen concentrate is not available.21,35,36 Cryoprecipitate 
and FFP can be either single donor or pooled.35 Single 
donor cryoprecipitate and FFP can be either virally 
inactivated (using methylene blue/visible light treatment) 
or non-virally inactivated.35 Pooled cryoprecipitate is 
non-virally inactivated whereas both virally inactivated 
(with solvent detergent treatment) and non-virally inac-
tivated pooled FFP exist.35 However, the single-step viral 
inactivation of cryoprecipitate and FFP is considered 
inferior (particularly against non lipid-enveloped viruses) 
compared with fibrinogen concentrates that have undergone 
2 viral inactivation steps.35 The amount of fibrinogen in 
cryoprecipitate and FFP varies but is lower than in fibrinogen 
concentrates.12 Cryoprecipitate is enriched in fibrinogen but 
methylene blue/visible light treatment of cryoprecipitate 
reduces fibrinogen activity by 40%.35 According to current 
guidelines, virally inactivated FFP should be preferred to 
non-virally inactivated cryoprecipitate unless volume over-
load poses unacceptable risks.35
Thrombotic complications have been reported in patients 
with afibrinogenemia following replacement therapy, 
including ischemic foot lesions, ischemic stroke, renal 
and ovarian vein thrombosis, deep venous thrombosis and 
pulmonary embolism.12,13,15,41–44 Patients with afibrinogenemia 
who also suffer from inherited thrombophilic disorders 
(eg, protein C deficiency) appear to be at higher risk for 
thrombosis after replacement therapy.43 In addition, the 
risk might be greater when cryoprecipitate is used since the 
latter contains substantial quantities of other coagulation 
factors (particularly von Willebrand factor and factor VIII).21 
In patients with afibrinogenemia who exhibited thrombosis 
after cryoprecipitate treatment, switching to fibrinogen 
concentrate reduced the risk of recurrent thrombosis.15 
The management of thrombotic complications in patients 
with afibrinogenemia is problematic because of their 
bleeding tendency. Some authors proposed the concomitant 
administration of replacement therapy with low-dose 
heparin.43 Others recommend use of compression stockings 
and low molecular weight heparin in patients with a history 
of thrombosis who are undergoing surgery.21 In patients who 
develop thrombotic complications following replacement 
therapy, some authors continue the latter if indicated and 
co-administer low-molecular-weight or unfractionated 
heparin.13,15 In patients who develop recurrent thrombotic 
complications despite treatment with heparin and aspirin, 
treatment with lepirudin, a direct thrombin inhibitor, appears 
to be effective.45
In contrast to hemophilia, development of fibrinogen 
inhibitors following replacement therapy has been very rarely 
reported in patients with afibrinogenemia.46,47 It was suggested 
that the infrequent development of fibrinogen inhibitor is due 
to the presence of trace amounts of circulating fibrinogen.21
Other treatments
Fibrin glue can be used in dental extractions and in superficial 
wounds.36 Tranexamic acid inhibits fibrinolysis by binding 
plasmin and might also be useful in the treatment of mucosal 
bleeding.35,36 It can be administered orally, intravenously 
or as a mouth wash.35 However, it might increase the risk 
of thrombosis and should be used with caution in patients 
with a history of thrombosis.36 It should also be avoided in 
pregnant women, in patients who had recently undergone 
surgery or are immobilized and in cases of hematuria.35,36 
Tranexamic acid should be given at a lower dose in patients 
with renal failure.35Vascular Health and Risk Management 2009:5 846
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In patients with splenic rupture, splenectomy after 
administering fibrinogen concentrate appears to be the 
treatment of choice.32,48 Conservative management with 
replacement therapy aiming at fibrinogen levels 1 g/L has 
been reported in patients who are stable after fluid replace-
ment.34 However, these patients appear to be at increased risk 
of recurrent splenic rupture.48
In patients with severe liver disease mandating liver 
transplantation, the latter also will cure afibrinogenemia since 
fibrinogen is synthesized in the liver.21,22
Prevention
Before surgery, fibrinogen levels should be raised to 1 g/L 
and maintained at this level until hemostasis is established 
and above 0.5 g/L until complete wound healing.36 However, 
many physicians appear to aim at higher fibrinogen levels.12 
All invasive procedures in patients with afibrinogenemia 
should take place in centers directly served by a hemophilia 
center.36
Prophylactic infusion of fibrinogen concentrate or 
cryoprecipitate has been reported, particularly after 
life-threatening bleeding episodes.12–15,49 Most patients are 
treated with weekly infusions but treatment every 2 weeks 
or once a month has also been used.12 However, the frequency 
of bleeding in an observational study was similar in patients 
treated on-demand and in those given prophylactic infusions.12 
In the same study, more than half of the patients on prophylactic 
infusion experienced breakthrough bleeding, including 
intracranial hemorrhage.12 According to current guidelines, 
secondary prophylactic treatment may be considered after life-
threatening bleeding (eg intracranial bleeding) with a target 
fibrinogen level of 0.5 g/L.36 Primary prophylactic infusion 
is not recommended because of the risk of transmission of 
infectious diseases and development of inhibitors, allergic 
reactions and thrombotic complications.5,36
Estrogen-progesterone combination can be used as 
prophylaxis in patients with menorrhagia.5,22,36,49,50 Oral 
contraceptives also appear to be effective for the prevention 
of follicle rupture-induced hemoperitoneum.18,19 However, 
oral contraceptives might increase the risk of thrombosis.22,51 
Antifibrinolytic agents (eg, tranexamic acid and aminocaproic 
acid) can be used as prophylaxis before dental procedures.5,36 
Intramuscular injections should be avoided in patients 
with afibrinogenemia.5 Patients should be vaccinated 
against hepatitis A and B by subcutaneous injection.36 
Prenatal diagnosis is possible when both parents are known 
heterozygotes for afibrinogenemia mutations or already have 
an affected child.52
Pregnancy
Fibrinogen appears to contribute to placental implantation.53 
Accordingly, there is an increased risk of spontaneous 
abortion in patients with afibrinogenemia, which occurs 
at 6 to 8 weeks of gestation if no replacement therapy 
is given.3,12,53–56 Patients with afibrinogenemia can have 
successful pregnancies if treated with fibrinogen concentrate 
or cryoprecipitate.3,13,49,53,55,57,58 However, preterm delivery 
appears to be more frequent in these women despite 
replacement therapy.53 Placental abruption has also been 
reported despite the administration of fibrinogen concentrate 
or cryoprecipitate.13,58
Replacement therapy should be instituted as soon 
as possible in pregnancy in order to prevent fetal loss, 
probably from the 5th week of gestation.5,36,53 It should be 
continued throughout the pregnancy aiming at fibrinogen 
levels 1.0 g/L.36 Hemorrhagic complications have been 
reported with lower fibrinogen levels.49 However, thrombotic 
complications have also been reported during replacement 
therapy in pregnancy.13 It appears that fibrinogen requirements 
increase as pregnancy progresses.13,53 During labor, some 
authors recommend higher levels (2.0 g/L) to prevent 
placental abruption.53 Both vaginal delivery and cesarean 
sections have been reported.53,59 During puerperium, lower 
fibrinogen levels appear to be sufficient to prevent bleeding.53 
Pregnancy should be managed in obstetric departments of 
hospitals that have a hemophilia center.36
Conclusions
Even though afibrinogenemia is a rare disorder, it might 
acquire greater importance in the future because of the 
immigration of Islamic populations where this disorder is 
more prevalent due to consanguineous marriages.60 Patients 
with afibrinogenemia should be referred to and registered with 
a hemophilia center.36 The development of new tests to iden-
tify higher risk patients and of safer replacement therapy will 
improve the management of these patients in the future.
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